In a urology clinic, the most valuable data is often the hardest to get. A patient’s detailed history, their symptom diary, the results of standardized questionnaires, all of it is critical for a diagnosis. Yet this information typically arrives in fragments, if it arrives at all, scribbled on paper forms or lost in the shuffle between a primary care referral and a specialist appointment. The result is a consultation that starts from scratch, burdened by administrative catch-up instead of focused on care.
CuraDia, a Montreal startup founded in 2025, is betting that a better-structured beginning can change that dynamic. Its product, Uro-OS, is a clinical operating system designed specifically for urology and pelvic medicine. It collects patient-reported information before the visit, structures it for clinical use, and supports physician-reviewed documentation [CuraDia, May 2026]. The company is currently at the prototype stage, with plans to onboard its first pilot clinics in the latter half of 2026 [CuraDia, May 2026].
A physician-in-the-loop workflow
The company’s approach is deliberately conservative from a regulatory standpoint. Uro-OS does not diagnose. Instead, it organizes. Patients complete a structured digital intake at home, which captures medical history and relevant, validated questionnaires. They can also log symptoms in a mobile-first three-day diary, replacing paper logs with cleaner data [CuraDia, May 2026].
This information flows to a clinician dashboard, presented as signal without interpretation. The physician reviews the compiled summary at the point of care, confirms the diagnosis, and only then does the system format an encounter note ready for the electronic medical record [CuraDia, May 2026]. This physician-in-the-loop model is a core part of CuraDia’s identity, a stance it articulates clearly to distance itself from fully automated diagnostic tools [CuraDia, May 2026]. The stated goals are straightforward: increase questionnaire completion, decrease the time clinicians spend reviewing disparate data, and cut documentation time [CuraDia, May 2026].
The founding duo: clinic insight and commercial build
The team is small, reported at between one and ten people, and built around a complementary founder pair [CuraDia, May 2026]. Dr. Christian Diab, the co-founder and medical director, is a practicing urologist and resident affiliated with McGill University. His public focus is on improving the structure and quality of patient data within his specialty, bringing the frontline clinical perspective to the product [CuraDia, May 2026].
Claudie Léger, co-founder and CEO, handles product direction, go-to-market, and early clinic partnerships. Her public profile notes responsibility for navigating Quebec’s specific privacy landscape, including Law 25 and PIPEDA compliance [CuraDia, May 2026]. The venture originated from an MBA project at ESG UQAM, suggesting an academic foundation that has since evolved into a commercial build [CuraDia, May 2026].
| Role | Name | Key Background |
|---|---|---|
| Co-Founder, CEO | Claudie Léger | Product, GTM, Quebec privacy/compliance (Law 25, PIPEDA); MBA project origin [CuraDia, May 2026][CuraDia, May 2026]. |
| Co-Founder, Medical Director | Dr. Christian Diab | Practicing urologist & resident, McGill University; focus on structured patient data in urology [CuraDia, May 2026][CuraDia, May 2026]. |
The path to pilot and proof
Public traction is, understandably for a company at this stage, yet to be demonstrated. CuraDia has no publicly named pilot customers or health system partnerships. Its appearance in the Startupfest Village directory in July 2026 categorized it as a HealthTech prototype, a fitting descriptor for its current phase [Startupfest, July 2026]. The next critical milestone is the planned pilot onboarding in Q3-Q4 2026. Success will be measured not by vanity metrics, but by tangible workflow improvements inside those initial clinics.
The company’s public materials do not detail a specific funding round, though it has secured some early capital [CuraDia, May 2026]. The absence of a named institutional investor suggests a friends-and-family or angel-backed beginning, which is typical for a pre-seed operation building an initial prototype. The resource focus appears to be on product development and securing those first clinical validation partners.
Navigating a crowded field without direct confrontation
The competitive landscape for digital health tools is vast, but CuraDia’s wedge is notably specific. It is not a general-purpose EMR, a telehealth platform, or a patient-facing symptom checker. Its bet is on becoming the structured data layer for a single specialty, starting with urology. This focus allows it to embed deeply into a niche workflow without directly challenging entrenched, broad-system incumbents.
The risks, however, are familiar to any healthtech startup seeking clinic adoption.
- Integration burden. The promise of EMR-ready notes is only valuable if the integration is smooth. Clinics are notoriously wary of new software that creates more work for IT staff or disrupts existing charting routines.
- Physician adoption. Even a tool designed to save time requires a change in habit. The clinician dashboard must be intuitive enough to become a natural first step in the consultation, not an extra tab to remember to open.
- Data sensitivity. Handling patient-reported information on sensitive urological and pelvic health conditions requires impeccable security and privacy safeguards, a non-negotiable table stake in Canadian healthcare.
CuraDia’s answer to these challenges lies in its founding composition and its narrow scope. Having a practicing urologist defining the product should, in theory, keep it aligned with real clinical needs. By focusing solely on pre-consultation data structuring, it aims to solve one discrete problem exceptionally well, hoping that a small win can pave the way for broader adoption.
The standard of care today
For patients dealing with conditions like urinary incontinence, pelvic pain, or prostate issues, the current pathway to a specialist is often inefficient. The referral process can take weeks or months. When the appointment finally arrives, the first portion is frequently consumed by the clinician manually extracting a history from the patient, who may struggle to recall precise symptom patterns. Paper diaries are easily lost or incomplete. This dynamic leaves less time for discussion, education, and collaborative treatment planning. CuraDia’s ambition is to shift that dynamic, giving the patient a clearer role in data collection and returning the precious minutes of the consultation to the practice of medicine itself.
The next twelve months are a critical validation window for the Montreal team. Observers should watch for two signals: the announcement of named pilot clinic partners and, more importantly, any published data from those pilots on metric improvements like reduced documentation time or increased patient-reported outcome completion rates. For CuraDia, the story will move from building a system to proving it works in the messy, real-world environment of a busy urology practice.
Sources
- [CuraDia, May 2026] CuraDia, The clinical operating system for urology | https://curadia.ca/
- [CuraDia, May 2026] Physician-in-the-loop: where AI belongs in clinical workflow | https://curadia.ca/blog/physician-in-the-loop-where-ai-belongs
- [Startupfest, July 2026] Startupfest Village Directory | https://www.startupfest.com/startupfest-village-directory